Actual Medicinal Product (AMP) Rivaroxaban 20mg tablets (Medreich Plc)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
No stability data in MCAs available but no theoretical concerns with product.
- Provenance
-
This recommendation is based on the products Xarelto 20mg tablets (Bayer plc) and rivaroxaban 20mg tablets (Krka UK Ltd).
- Generic
- Rivaroxaban
- Formulation
- Rivaroxaban 20mg tablets
-
Rivaroxaban
-
Rivaroxaban 20mg tablets
-
Rivaroxaban 20mg tablets (Medreich Plc)
-
-
Rivaroxaban 15mg tablets and Rivaroxaban 20mg tablets